Researchers will need to develop multiple types of coronavirus vaccines to address the incredible scale of the outbreak, said Harvard University vaccine researcher Drs. Dan Barouch, to Yahoo Finance in a recent interview.
He expressed optimism about the many faxes in development, but warned that even faxes that prove effective may have weaknesses as side effects, requiring other versions to make up for their shortcomings.
“We have more than 300 million people in this country and more than 7 billion people in the world,” he said. “No vaccine developer will be able to deliver a vaccine to the world market.”
“So I actually think we not only want to, but we really need multiple vaccines to be successful,” said Barouch, who heads the Center for Virology and Vaccine Research and has partnered with pharmaceutical company Johnson & Johnson (JNJ). about the development of a vaccine.
There are well over 100 faxes in development and 32 are currently undergoing human trials, including eight candidates who have entered Phase three trials with thousands of subjects, reports the New York Times.
Developers are getting several faxes in part from the use of varied techniques, Barouch said. Last month, pharmaceutical companies Moderna (MRNA) and Pfizer (PFE) announced that each had begun phase three trials on candidates developed using synthetic genetic material, while other vaccines in late-stage tests using a common cold virus modified with a gene of SARS-CoV-2.
Next month, Johnson & Johnson will launch the largest trial with a late-stage coronavirus vaccine, involving 60,000 people in the U.S. and other countries, the company confirmed on Thursday.
The first vaccine may be ready by the end of the year, but will not be widely available until 2021, Barouch said, reflecting a similar prediction made last month by top US official official infectious disease Dr Anthony Fauci.
But an initial success will not end the global effort now underway to develop faxes, as each version will have strengths and weaknesses, Barouch said.
“It is quite possible that there may be multiple faxes that prove safe and effective, at least that would be my hope,” says Barouch. “The more faxes available, the better.”
“Because each vaccine can have some pros and cons: Some may be more effective, some may have different side effects. profiles can be particularly good in the elderly as well as in the young populations, some may have different costs that have to do with it, ‘he said.
Barouch spoke with Yahoo Finance Editor-in-Chief Andy Serwer in an episode of “Influencers with Andy Serwer,” a weekly interview series with leaders in business, politics and entertainment.
The U.S. government and Johnson & Johnson have invested a combined $ 1 billion in a vaccine candidate co-developed by Beth Israel Deaconess Medical Center, where Barouch heads the Center for Virology and Vaccine Research. The vaccine is currently undergoing phase one and two tears, but intends to begin phase three trials next month, Barouch said.
The fax researcher Harvard University Dr. Dan Barouch appears on “Influencers with Andy Serwer.”
The Trump administration has provided financial support for four faxes through Operation Warp Speed, which has set a target of 300 million doses by the end of 2021. Several faxes are in development in China and Australia, while England and Germany have faxes. produced that are currently human are threads.
“The global fax effort spans today’s leading technologies in multiple arenas. That being said, I think we will see which ones are the safest, are the most effective, if the most sustainable and ultimately the most viable for this pandemic, “he adds.
